Innate Pharma (IPHA) Profit After Tax (2019 - 2025)

Innate Pharma has reported Profit After Tax for 7 years, with the latest figure at -$57.2 million in Q4 2025.

• For the quarter ending Q4 2025, Profit After Tax fell 8.28% year-over-year to -$57.2 million; the trailing twelve-month figure through Dec 2025 stood at -$144.9 million (down 73.14% YoY), and the FY2025 full-year result was -$57.2 million, down 8.28% from the prior year.
• Profit After Tax for Q4 2025 stood at -$57.2 million, down from -$24.2 million in the prior quarter.
• The five-year high for Profit After Tax was $4.0 million in Q2 2023, with the low at -$60.4 million in Q4 2021.
• Historically, Profit After Tax has averaged -$28.2 million across 5 years, with a median of -$26.7 million in 2024.
• Annual changes were most pronounced in 2022 — Profit After Tax soared 99.9% — and 2023, when it sank 13639.78%.
• Innate Pharma's Profit After Tax stood at -$60.4 million in 2021, then soared by 99.9% to -$59279.4 in 2022, then slumped by 13639.78% to -$8.1 million in 2023, then tumbled by 549.05% to -$52.9 million in 2024, then decreased by 8.28% to -$57.2 million in 2025.
• The last three Profit After Tax figures came in at -$57.2 million (Q4 2025), -$24.2 million (Q2 2025), and -$52.9 million (Q4 2024), per Business Quant data.